Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
76 studies found for:    "Kennedy disease"
Show Display Options
RSS Create an RSS feed from your search for:
"Kennedy disease"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed
Has Results
Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)
Conditions: Kennedy's Disease;   Spinal and Bulbar Muscular Atrophy
Interventions: Drug: Dutasteride;   Drug: Placebo
2 Active, not recruiting MRI in Patients With Kennedy Disease
Conditions: Bulbo-Spinal Atrophy, X-Linked;   Kennedy Disease
Intervention: Other: No intervention, observational
3 Completed Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy
Conditions: Spinobulbar Muscular Atrophy;   Kennedy's Disease
Interventions: Drug: Goserelin;   Procedure: Electrophysiologic study;   Procedure: tissue biopsy
4 Completed Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy
Condition: Spinal and Bulbar Muscular Atrophy
Interventions: Drug: BVS857;   Drug: Placebo
5 Active, not recruiting Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
Condition: Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Intervention: Drug: Enzalutamide
6 Unknown  High Intensity Training in Patients With Spinal and Bulbar Muscular Atrophy
Conditions: Spinal and Bulbar Muscular Atrophy;   Healthy Subjects
Interventions: Other: Supervised high intensity training;   Other: Optional training;   Other: Control period;   Other: Unsupervised High intensity training
7 Completed Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors
Condition: Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor
Intervention: Drug: AZD5312
8 Completed Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease
Conditions: Spinal Muscular Atrophy;   Amyotrophic Lateral Sclerosis;   Spinobulbar Muscular Atrophy
Interventions: Drug: leuprolide;   Drug: testosterone
9 Terminated A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)
Conditions: Metastatic Breastcancer;   Estrogen Receptor Positive Breast Cancer;   Estrogen Receptor Negative Neoplasm;   Progesterone Receptor Positive Tumor;   Progesterone Receptor Negative Neoplasm;   Androgen Receptor Gene Overexpression
Intervention: Drug: DHEA
10 Not yet recruiting Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer
Conditions: Androgen Receptor Positive;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Enobosarm;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
11 Recruiting Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Conditions: Advanced Epithelial Ovarian;   Recurrent Epithelial Ovarian;   Fallopian Tube;   Primary Peritoneal Carcinoma
Intervention: Drug: Enzalutamide
12 Not yet recruiting A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: LY2452473;   Drug: Placebo
13 Completed Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women
Conditions: Libido;   Receptors, Androgen;   Polymorphism, Genetic;   Androgen Effect
Intervention:
14 Recruiting Study of Hepatic Function in Patients With Spinal and Bulbar Muscular Atrophy
Conditions: Liver;   Motor Neuron Disease
Intervention:
15 Recruiting Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
Condition: Salivary Cancer
Intervention: Drug: enzalutamide
16 Withdrawn STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling
Condition: Adenocarcinoma of the Prostate
Interventions: Drug: STA9090;   Drug: STA9090 with Dutasteride
17 Recruiting Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Condition: Metastatic Breast Cancer
Intervention: Drug: Orteronel
18 Active, not recruiting The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: ARN-509;   Drug: LHRH Agonist
19 Terminated GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Triple Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: cisplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI;   Drug: GDC -0941
20 Recruiting A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
Condition: Prostate Cancer
Interventions: Biological: pTVG-AR;   Biological: gm-csf

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.